Zymergen and similar platform companies emerged around 2012-2015, with the promise to use synthetic biology to make materials, food, and industrial products. They combined cheap DNA sequencing and editing tools to create a platform for editing cells more efficiently. However, due to multiple factors such as hype and supply chain issues, these companies have struggled and faced significant setbacks.